Back to Journals » OncoTargets and Therapy » Volume 10

HOXD-AS1 functions as an oncogenic ceRNA to promote NSCLC cell progression by sequestering miR-147a

Authors Wang Q, Jiang S, Song A, Hou S, Wu Q, Qi L, Gao X

Received 12 June 2017

Accepted for publication 9 August 2017

Published 28 September 2017 Volume 2017:10 Pages 4753—4763

DOI https://doi.org/10.2147/OTT.S143787

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Carlos Vigil Gonzales

Qinghua Wang,1–3,* Shujun Jiang,1,2,* Anying Song,1,2 Siyuan Hou,1,2 Qinfeng Wu,4 Longju Qi,5 Xiang Gao1,2

1State Key Laboratory of Pharmaceutical Biotechnology, 2MOE Key Laboratory of Model Animal for Disease Study, Model Animal Research Center, Nanjing Biomedical Research Institute, Nanjing University, Nanjing, 3Laboratory Animal Center, Nantong University, 4Department of Rehabilitation, Affiliated Hospital of Nantong University, Nantong University, 5Interventional Therapy Department of the Third People’s Hospital of Nantong City, Nantong University, Nantong, People’s Republic of China

*These authors contributed equally to this work

Abstract: Non-small cell lung cancer (NSCLC) is one of the most common malignancies worldwide, and it occurs at a higher frequency in males. HOXD-AS1, an important cancer-associated long noncoding RNA (lncRNA), contributes to the development and progression of several cancers. However, the exact roles of HOXD-AS1 in NSCLC progression are still unknown. Here, we investigated the underlying mechanisms of HOXD-AS1 in human NSCLC tissues. We found that lncRNA HOXD-AS1 was specifically upregulated (P<0.001) in NSCLC tissues and promoted cancer cell growth by targeting miR-147a. Moreover, HOXD-AS1 expression positively correlated with NSCLC clinical pathologic characteristics (tumor size, P=0.006; tumor stage, P=0.044; recurrence, P=0.031) and survival rate (P=0.003). HOXD-AS1 knockdown reduced proliferation and promoted apoptosis of NSCLC cells. The dual-luciferase reporter assay showed that HOXD-AS1 could negatively regulate the expression of miR-147a. miR-147a inhibition abrogated the effect of HOXD-AS1 knockdown on the proliferation and apoptosis of NSCLC cells. Furthermore, HOXD-AS1 positively regulated the expression of pRB (a tumor suppressor protein) in NSCLC cells. Taken together, our data indicated that HOXD-AS1 might be an oncogenic lncRNA that promotes proliferation of NSCLC and could be a therapeutic target in NSCLC.

Keywords: non-small cell lung cancer, HOXD-AS1, proliferation, miR-147a

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]